CoChat

The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK

Jugrin, Anamaria Vera, Ustyugova, Anastasia, Urbich, Michael, Sunderland, Tom, Lamotte, Mark · 2015 · Thrombosis and Haemostasis

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

The relative efficacy and safety of dabigatran etexilate and warfarin have been evaluated in two head-to-head, phase III, treatment of acute venous thromboembolism (VTE) trials, and one extended prophylaxis trial, in patients with high risk of recurrent VTE. Dabigatran etexilate demonstrated similar efficacy to warfarin, and was associated with a reduced risk of major or clinically relevant bleeds. Based on results of these trials, and real-life disease prognosis following discontinuation of anticoagulation treatment, we evaluated the cost-utility of dabigatran etexilate compared with warfarin in six months anticoagulation, and in extended, up to 24 months anticoagulation, in patients with acute VTE, acute deep-vein thrombosis (DVT) or acute, symptomatic, pulmonary embolism (PE). Costs were analysed from the perspective of the National Health Services (NHS) and Public Social Services (PSS) in England and Wales. Outcomes were quantified in quality-adjusted life years (QALY). The estimated incremental, lifetime cost/QALY gain following acute, symptomatic VTE (DVT or PE) was £1,252/QALY when dabigatran etexilate or warfarin were administered for up to six months treatment. In treatment of acute, symptomatic PE and in DVT respective ratios were £1,767/QALY and £1,075/QALY. In extended, up to 24 months anticoagulation, dabigatran etexilate projected costs/QALY of £8,242/QALY, when compared with warfarin. Results obtained herein were robust across a number of sensitivity analyses a…

Overview

Integrity signals

Registry

Crossref · 10.1160/th14-12-1027

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. Prandoni, 1997, Haematologica, 82, 423

Cited by

See all 12

Metadata

Authors
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M.
Affiliations
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (United Kingdom) (GB)
Corresponding author
Lamotte, Mark
Venue
Thrombosis and Haemostasis
Published
2015
Volume
114
Issue
10
Pages
778-792
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2163451556
Cited by
11
References
25
Citations by year
2025: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 3 · 2016: 2 · 2015: 1
FWCI
2.04
Type
journal article
Language
en
Open access
closed
Locations
  • Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim International GmbH
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
dabigatran etexilate, warfarin, venous thromboembolism, deep vein thrombosis, pulmonary embolism, long-term anticoagulation, cost-utility analysis, quality-adjusted life years, cost per QALY, bleeding risk, anticoagulation, National Health Service costs
MeSH terms
Dabigatran, Acute Disease, Anticoagulants, Cost-Benefit Analysis, Drug Administration Schedule, United Kingdom, Hemorrhage, Humans, Pulmonary Embolism, State Medicine, Time Factors, Warfarin, Drug Costs, Treatment Outcome, Models, Economic, Quality-Adjusted Life Years, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK. https://app.cochat.ai/papers/10.1160/th14-12-1027
The paper
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015). The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK. Thrombosis and Haemostasis. https://doi.org/10.1160/th14-12-1027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.